Sökning: WFRF:(van Vollenhoven Ronald)
> (2015-2019) >
Infliximab Versus C...
-
Eriksson, Jonas KKarolinska Institutet
(författare)
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis : Results of a Randomized Swedish Trial
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:a8338933-f4c4-4a53-a8e4-f69ed1e19339
-
https://lup.lub.lu.se/record/a8338933-f4c4-4a53-a8e4-f69ed1e19339URI
-
https://doi.org/10.1002/acr.22899DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:135081753URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Objective To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) randomized to addition of infliximab or conventional combination treatment. Methods Multicentre, two-arm, parallel, randomized, active-controlled, open-label trial. RA patients with <1y symptom duration were recruited from 15 rheumatology clinics in Sweden between 2002-2005. Patients who did not achieve low disease activity after 3-4 months methotrexate therapy were randomized to addition of infliximab or conventional combination treatment with sulfasalazine+hydroxychloroquine. Yearly sick leave and disability pension days over 7 years after randomization were retrieved from nationwide registers kept by the Swedish Social Insurance Agency. Results Of 210 working age patients, 109 were randomized to infliximab (mean age=48.4y, 73% women) and 101 to conventional treatment (48.7y, 77%). The year before randomization the mean number of annual work days lost was 127 in the infliximab arm and 118 in the conventional treatment group (mean difference, 9; 95%CI, -23 to 39). Compared to the year before randomization, the mean changes at 7 years were -25 days in the infliximab and -26 days in the conventional treatment group (adjusted mean difference, 10; 95%CI, -25 to 46). The mean cumulative work loss days was 846 in the infliximab group and 701 in the conventional treatment group (adjusted mean difference, 104; 95%CI, -56 to 284). Conclusions Long-term work loss improved significantly in early RA randomized to infliximab+methotrexate or conventional combination therapy. No difference was detected between strategies, and the level of work loss days remained twice that observed in the general population.TRIAL REGISTRATION NUMBER: NCT00764725 This article is protected by copyright. All rights reserved.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
KARLSSON WALLMAN, JOHANKarolinska Institutet,Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-jnk
(författare)
-
Miller, HeatherKarolinska Institutet
(författare)
-
Petersson, Ingemar FLund University,Lunds universitet,Ortopedi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Orthopaedics (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)ort-ipe
(författare)
-
Ernestam, SofiaKarolinska Institutet
(författare)
-
Vivar, NancyKarolinska Institutet
(författare)
-
van Vollenhoven, Ronald FKarolinska Institutet
(författare)
-
Neovius, MartinKarolinska Institutet
(författare)
-
Karolinska InstitutetReumatologi och molekylär skelettbiologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Arthritis Care and Research: Wiley68:12, s. 1758-17662151-46582151-464X
Internetlänk
Hitta via bibliotek
Till lärosätets databas